These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25740389)

  • 1. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study).
    Kinugawa K; Inomata T; Sato N; Yasuda M; Shimakawa T; Bando K; Mizuguchi K
    Int Heart J; 2015; 56(2):137-43. PubMed ID: 25740389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tolvaptan in heart failure patients with volume overload.
    Kinugawa K; Sato N; Inomata T; Shimakawa T; Iwatake N; Mizuguchi K
    Circ J; 2014; 78(4):844-52. PubMed ID: 24670835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L; Bai H; Zhu WL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y; Meno H
    Heart Vessels; 2018 Feb; 33(2):145-154. PubMed ID: 28815407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
    Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S
    Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.
    Sato N; Sugiura T; Nagasaki R; Suzuki K; Ito K; Kato T; Inukai S; Saitoh S
    Pediatr Int; 2015 Oct; 57(5):1020-2. PubMed ID: 26508187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
    Int Heart J; 2015; 56(2):213-8. PubMed ID: 25740399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
    Okabe T; Yakushiji T; Igawa W; Ono M; Kido T; Ebara S; Yamashita K; Yamamoto MH; Saito S; Hoshimoto K; Amemiya K; Isomura N; Araki H; Ochiai M
    Cardiovasc Ther; 2015 Oct; 33(5):275-81. PubMed ID: 26122275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment.
    Hirai K; Shimomura T; Moriwaki H; Ishii H; Shimoshikiryo T; Tsuji D; Inoue K; Kadoiri T; Itoh K
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1177-1183. PubMed ID: 27395406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
    Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
    [No Abstract]   [Full Text] [Related]  

  • 14. A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure.
    Kinugawa K; Sato N; Inomata T; Yasuda M; Shimakawa T; Fukuta Y
    Int Heart J; 2019 Sep; 60(5):1123-1130. PubMed ID: 31484861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who Needs Longer Tolvaptan Treatment?
    Kinugawa K; Inomata T; Sato N; Yasuda M; Shimakawa T; Bando K; Fukuta Y
    Int Heart J; 2017 Feb; 58(1):30-35. PubMed ID: 28111410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.
    Tamura Y; Kimura M; Takei M; Ono T; Kuwana M; Satoh T; Fukuda K; Humbert M
    Eur Respir J; 2015 Jul; 46(1):283-6. PubMed ID: 25929949
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure　- Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study.
    Kinugawa K; Sato N; Inomata T; Yasuda M; Shimakawa T; Fukuta Y
    Circ J; 2019 Jun; 83(7):1520-1527. PubMed ID: 31118355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
    Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.